FOLH1 and prostate carcinoma: Similar results of a 50% reduction in PSA levels in 44.2% of patients with castration-resistant prostate cancer were reported in another study of 177Lu-PSMA-617 therapy, as well as increased overall survival in responder patients in comparison to non-responders.